Hetero to Market Dr Reddy's Hepatitis drug-Resof

Hetero to Market Dr Reddy
Highlights

Hetero to Market Dr Reddy\'s Hepatitis drug-Resof Dr Reddy’s Laboratories has entered into an agreement with Hetero to distribute and market Sofosbuvir 400 mg tablets used in treatment of Chronic Hepatitis C, under the brand name Resof, in India.

Dr Reddy’s Laboratories has entered into an agreement with Hetero to distribute and market Sofosbuvir 400 mg tablets used in treatment of Chronic Hepatitis C, under the brand name Resof, in India.


According to the World health Organization (WHO), close to 12 Million Indians suffer from Chronic Hepatitis C, a disease that can seriously affect the liver, leading to potentially life-threatening complications, including cancer of the liver Complications arising out of untreated Hepatitis C can precipitate faster in co-morbid conditions, such as Diabetes.


Resof is a breakthrough medicine and will simplify the traditional and complicated treatment options available today, allowing patients suffering from Chronic Hepatitis C access to a far more affordable and effective treatment regimen, as compared to existing ones.

Dr. Reddy’s Co-Chairman and CEO, G V Prasad, commented “the launch of Resof is in line with Dr. Reddy’s philosophy of “Innovative medicine at an affordable price” and will provide significant relief to patients, resulting in potential cure and a high barrier to resistance at an affordable price for those living with Hepatitis C.

Show Full Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
Subscribed Failed...
Subscribed Successfully...
More Stories


Top